Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 16335 [2014-06451]
Download as PDF
Federal Register / Vol. 79, No. 57 / Tuesday, March 25, 2014 / Notices
emcdonald on DSK67QTVN1PROD with NOTICES
exposed to radiation but for whom it is not
feasible to estimate their radiation dose, and
on whether there is a reasonable likelihood
that such radiation doses may have
endangered the health of members of this
class. The Subcommittee on Procedures
Review was established to aid the ABRWH in
carrying out its duty to advise the Secretary,
HHS, on dose reconstructions. The
Subcommittee on Procedures Review is
responsible for overseeing, tracking, and
participating in the reviews of all procedures
used in the dose reconstruction process by
the NIOSH Division of Compensation
Analysis and Support (DCAS) and its dose
reconstruction contractor (Oak Ridge
Associated Universities—ORAU).
Matters For Discussion: The agenda for the
Subcommittee meeting includes: discussion
of procedures in the following ORAU and
DCAS technical documents: ORAU Team
Technical Information Bulletin (OTIB)0034
(‘‘Internal Dose Coworker Data for X–10’’),
OTIB 0054 (‘‘Fission and Activation Product
Assignment for Internal Dose-Related Gross
Beta and Gross Gamma Analyses’’), OTIB
0083 (‘‘Dissolution Models for Insoluble
Plutonium 238’’), Program Evaluation Report
(PER) 011 (‘‘K–25 [Technical Basis
Document] TBD and TIB Revisions’’), PER
020 (‘‘Blockson TBD Revision’’), PER 031
(‘‘Y–12 TBD Revisions’’), PER 033
(‘‘Reduction Pilot Plant TBD Revision’’), PER
038 (‘‘Hooker Electrochemical TBD
Revisions’’); Update on Review of ORAU
Team Report 0053 (‘‘Stratified Co-Worker
Sets’’); discussion of estimating radiation
doses associated with localized skin
exposures to uranium at Atomic Weapons
Employer facilities; and a continuation of the
comment-resolution process for other dose
reconstruction procedures under review by
the Subcommittee.
The agenda is subject to change as
priorities dictate.
Contact Person For More Information:
Theodore Katz, Designated Federal Officer,
NIOSH, CDC, 1600 Clifton Road NE.,
Mailstop E–20, Atlanta Georgia 30333,
Telephone (513) 533–6800, Toll Free
1(800)CDC–INFO, Email ocas@cdc.gov. The
Director, Management Analysis and Services
Office, has been delegated the authority to
sign Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
16335
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control; Special
Emphasis Panel (SEP): Initial Review
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Research Approaches to
Improve the Care and Outcomes of
People Living with Spina Bifida, FOA
DD14–002, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
The meeting announced below
concerns A Creutzfeldt-Jakob Disease
(CJD) Lookback Study: Assessing the
Risk of Blood Borne Transmission of
Classic Forms of Creutzfeldt-Jakob
Disease, Funding Opportunity
Announcement (FOA) CK14–005, initial
review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Times and Dates: 9:00 a.m.–6:00 p.m.,
April 14, 2014 (Closed).
9:00 a.m.–6:00 p.m., April 15, 2014
(Closed).
9:00 a.m.–6:00 p.m., April 16, 2014
(Closed).
9:00 a.m.–6:00 p.m., April 17, 2014
(Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters For Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Research Approaches to
Improve the Care and Outcomes of People
Living with Spina Bifida, FOA DD14–002,
initial review.’’
Contact Person For More Information: M.
Chris Langub, Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway NE.,
Mailstop F–80, Atlanta, Georgia 30341,
Telephone: (770) 488–3585, EEO6@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Time And Date: 2:00 p.m.–3:30 p.m., EST,
April 15, 2014 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters For Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘A Creutzfeldt-Jakob Disease
(CJD) Lookback Study: Assessing the Risk of
Blood Borne Transmission of Classic Forms
of Creutzfeldt-Jakob Disease, FOA CK14–005,
initial review.’’
Contact Person For More Information:
Gregory Anderson, M.S., M.P.H., Scientific
Review Officer, CDC, 1600 Clifton Road NE.,
Mailstop E60, Atlanta, Georgia 30333,
Telephone: (404) 718–8833.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2014–06451 Filed 3–24–14; 8:45 am]
BILLING CODE 4163–18–P
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2014–06450 Filed 3–24–14; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
[FR Doc. 2014–06452 Filed 3–24–14; 8:45 am]
Disease, Disability, and Injury
Prevention and Control; Special
Emphasis Panel (SEP): Initial Review
BILLING CODE 4163–18–P
The meeting announced below
concerns Grants for Injury Control
VerDate Mar<15>2010
18:16 Mar 24, 2014
Jkt 232001
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
E:\FR\FM\25MRN1.SGM
25MRN1
Agencies
[Federal Register Volume 79, Number 57 (Tuesday, March 25, 2014)]
[Notices]
[Page 16335]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-06451]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns A Creutzfeldt-Jakob Disease
(CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of
Classic Forms of Creutzfeldt-Jakob Disease, Funding Opportunity
Announcement (FOA) CK14-005, initial review.
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the aforementioned meeting:
Time And Date: 2:00 p.m.-3:30 p.m., EST, April 15, 2014
(Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters For Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in
response to ``A Creutzfeldt-Jakob Disease (CJD) Lookback Study:
Assessing the Risk of Blood Borne Transmission of Classic Forms of
Creutzfeldt-Jakob Disease, FOA CK14-005, initial review.''
Contact Person For More Information: Gregory Anderson, M.S.,
M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE.,
Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2014-06451 Filed 3-24-14; 8:45 am]
BILLING CODE 4163-18-P